Saturday, 15th February 37th Lorne Cancer Conference 2025

• Innovative Strategies to Improve CAR T Cell Therapy for Prostate Cancer - Renea A Taylor
• Preclinical evaluation of farletuzumab ecteribulin (FZEC) and MORAb-109, antibody-drug conjugates (ADCs) targeting folate receptor alpha and mesothelin, in high-risk gynaecological cancers. - Cassandra J Vandenberg
• Targeting androgen receptor to prevent cell state plasticity and chemotherapy resistance in triple-negative breast cancer - Heloisa H Milioli
• What does sex have to do with cancer immunotherapy? - Amy E Moran
• Publishing in Nature Journals - Safia Danovi

Session Sponsored by:

• Environmental challenge rewires functional connections among human genes - Luke Gilbert
• Informing therapeutic approaches for p53 mutant cancers - Gemma Kelly
• Delineating functional drivers of esophageal adenocarcinoma to identify synthetic lethal interactions - Nicholas Clemons
• Chromatin remodelling with combined FACT and BET inhibition disrupts oncogenic transcription in Diffuse Midline Glioma - Holly Holliday
• Molecular mechanisms of epigenetic regulation - Qi Zhang

Session Sponsored by:

CRISPR Screens, TCR/BCR Sequencing and other approaches for Cancer Drug Target and Biomarker Discovery and Validation

Speakers
Alex Chenchik, PhD, President & Chief Scientist - Cellecta
Paul Diehl, PhD, Chief Operating Officer - Cellecta

Pre-register your attendance via the Portal Add-Ons.

• Intravital assessment of drug response in pancreatic cancer using biosensor imaging - Paul Timpson
• Tools for targeting glioma stem cell quiescence - Lachlan Harris
• Targeting myoferlin-dependent ER/Golgi vesicle trafficking reprograms cancer-associated fibroblasts and tackles stromal aggressiveness in pancreatic cancer. - Raphael Peiffer

Session Sponsored by:

• Epigenetic control of tumor associated macrophages – targeting the BAF nucleosome remodeling complex - Helen M McRae

• Tumour heterogeneity and its impact on disease progression and therapy response.  - Gregory Hannon